Latest Earnings Results: Q2 '26
Estimated EPS
-$0.39
Reported EPS
---
Surprise
---
Estimated Rev
$215M
Reported Rev
---
Surprise
---
• Reported GAAP EPS of -$0.47 down -62.07% YoY • Reported revenue of $199.91M down -5.94% YoY • Apellis Pharmaceuticals Inc. anticipates its cash and cash equivalents, combined with projected sales from EMPAVELI and SYFOVRE, will fund operating expenses and capital expenditures for at least the next 12 months.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$0.39 | -- | -- | N/A |
Q1 '26 | -$0.24 | -- | -- | N/A |
Q4 '25 | -$0.38 | -$0.47 | -24.25% | MISSED |
Q3 '25 | $1.58 | $1.67 | 5.78% | BEAT |
Q2 '25 | -$0.48 | -$0.33 | 31.64% | BEAT |